Loading...
NPI 1093891608 · Waterbury, CT · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Angela Bosjolie is a ophthalmology physician provider located in Waterbury, Connecticut. This profile covers 15 Medicare and 7 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Angela Bosjolie |
| Address | 1201 W Main St Ste 100 |
| City | Waterbury |
| State | CT |
| ZIP | 06708 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | October 27, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.2M |
| Medicaid | $0 |
Practice appears built around intravitreal anti-VEGF therapy: J0178 (aflibercept) drives $978.5K of Medicare revenue (82.6% of this provider's total Medicare revenue) with 1.4K claims, indicating the clinical workflow is heavily procedure-driven toward retinal injection services rather than primarily office-based evaluation. Supporting codes such as 67028 (628 claims, $64.1K, 5.4%) and retinal imaging codes are present but generate only a fraction of the revenue that J0178 produces.
Revenue is highly concentrated in a very small number of services: the precomputed top 3 Medicare codes by revenue account for 91.9% of this provider's total Medicare revenue, specifically J0178 at 82.6%, 67028 at 5.4%, and 92014 at 3.8%. This concentration means overall Medicare revenue ($1.2M lifetime) depends largely on ongoing access to and billing for those key injection and procedure codes.
This provider is effectively single-payer in the dataset: lifetime Medicare revenue is $1.2M while reported Medicaid revenue is $0, indicating no material Medicaid billing on file. That payer mix implies the provider’s operational and contracting exposure is concentrated with Medicare reimbursement policies and fee schedules rather than a diversified public-payer mix.
Despite J0178 being the dominant revenue source, the provider’s national standing for that code is modest: J0178 ranks #885 of 3204 providers nationally (72th percentile; typical, unremarkable volume for this code). In other words, revenue reliance on aflibercept is high at this practice, but the provider’s injection volume is similar to many peers rather than being a national outlier or dominant center.
Imaging and diagnostics show meaningful presence relative to injection services: 92134 (retinal OCT imaging) recorded 1.1K claims for $35.7K (3.0% of Medicare revenue) and ranks #2014 of 26868 providers nationally (93th percentile; typical, unremarkable volume for this code). The coexistence of high-volume OCT (92134) with dominant injection billing (J0178) is consistent with a retina-focused workflow where imaging supports frequent intravitreal treatments.
Office E/M and new-patient comprehensive exams contribute modestly to revenue compared with injections: 92014 (established comprehensive eye exam) produced $45.2K (3.8%), 99214 produced $26.2K (2.2%), 99213 $8.2K (0.7%), and 99212 $8K (0.7%). This mix indicates the practice generates most income from procedures and imaging tied to retinal care rather than from higher-volume E/M billing.
The provider has long-standing Medicare enrollment and an established billing history: NPI enumerated 2006-10-27 (~20 years ago) with lifetime Medicare revenue of $1.2M. Tenure of roughly two decades combined with concentrated procedure billing suggests a sustained, specialized practice pattern focused on retinal services over time.
Several codes register as low-volume or below-peer benchmarks despite the overall procedure focus: J9035 (bevacizumab) shows only 36 claims and $2K (0.2% of Medicare revenue) and ranks #1612 of 1852 providers nationally (12th percentile; typical, unremarkable volume), while 67228 (retinal laser) records 19 claims and $5.1K (0.4%) and ranks #452 of 648 providers nationally (26th percentile; typical, unremarkable volume). These patterns point to limited use of alternative injectable agents and laser treatments relative to the dominant aflibercept-driven practice model.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
15 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,410 | $690 | $978.5K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 630 | $100 | $64.1K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 480 | $100 | $45.2K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,120 | $30 | $35.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 270 | $100 | $26.2K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 110 | $70 | $8.2K |
| 99212 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,… | 180 | $40 | $8K |
| 67228 | In retinopathy, tiny new vessels grow profusely and fibrous tissue proliferates in between the layers of the retina, which may extend into the optic nerve and vitreous, clear gel that fills the space… | 20 | $270 | $5.1K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 30 | $120 | $3.9K |
| 92004 | The provider performs a comprehensive level ophthalmological evaluation of a new patient and initiates a diagnostic and treatment program for one or more visits. | 30 | $110 | $2.8K |
Showing 1–10 of 15
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 15 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
15 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 12 | 40 | 830 | $690 | $713.1K |
| 67028 | 26 | 50 | 540 | $100 | $66.4K |
| 92014 | 71 | 580 | 100 | $90 | $18.6K |
| 92235 | 21 | 30 | 40 | $110 | $14.8K |
| 99214 | 1,140 | 6,480 | 90 | $90 | $14.2K |
| J9035 | 28 | 30 | 130 | $50 | $10.4K |
| 67228 | 5 | 10 | 20 | $280 | $8.5K |
| 99213 | 2,249 | 6,440 | 70 | $60 | $8.1K |
| 92134 | 27 | 320 | 60 | $30 | $7.7K |
| 92004 | 222 | 410 | 30 | $110 | $5.2K |
Showing 1–10 of 15
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 80 | $0 | $0 |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 60 | $0 | $0 |
| 92015 | The provider determines the process of determining if a patient's vision is less than 20/20 and by what amount so that corrective lenses or contact lenses can be prescribed and produced. | 10 | $0 | $0 |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 130 | $0 | $0 |
| 99212 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,… | 40 | $0 | $0 |
| J0178 | Injection, aflibercept, 1 mg | 50 | $0 | $0 |
| J9035 | Injection, bevacizumab, 10 mg | 20 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Connecticut providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Connecticut median
7 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 18 | 20 | 1,420 | $570 | $2.4M |
| J9035 | Injection, bevacizumab, 10 mg | 16 | 20 | 600 | $180 | $329.8K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 23 | 20 | 1,990 | $40 | $217.8K |
| 92015 | The provider determines the process of determining if a patient's vision is less than 20/20 and by what amount so that corrective lenses or contact lenses can be prescribed and produced. | 434 | 440 | 1,200 | $30 | $118.2K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 327 | 410 | 700 | $40 | $99.1K |
| 99212 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,… | 454 | 580 | 230 | $20 | $32.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 34 | 60 | 290 | $10 | $31.7K |
Other providers in the same ZIP code as Angela Bosjolie, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.